ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.065,44
-1,55%
S&P 500
5.702,55
-0,19%
US Dollar vs BRL
5,41869
-1,75%
Bitcoin
62.969,19
-0,64%
Brent Oil
74,135
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Terns Pharmaceuticals Inc (TERN)

  7. Terns Pharmaceuticals Inc (TERN) Notícias

TERN

Terns Pharmaceuticals (TERN)

Terns Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TERN
DataHoraFonteTítuloCódigoCompanhia
12/09/202420:00GlobeNewswire Inc.Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:TERNTerns Pharmaceuticals Inc
12/09/202407:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TERNTerns Pharmaceuticals Inc
11/09/202417:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TERNTerns Pharmaceuticals Inc
10/09/202423:50GlobeNewswire Inc.Terns Announces Pricing of Upsized $150.15 Million Public OfferingNASDAQ:TERNTerns Pharmaceuticals Inc
09/09/202417:01GlobeNewswire Inc.Terns Announces Proposed Public OfferingNASDAQ:TERNTerns Pharmaceuticals Inc
09/09/202408:05GlobeNewswire Inc.Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of ObesityNASDAQ:TERNTerns Pharmaceuticals Inc
05/08/202418:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TERNTerns Pharmaceuticals Inc
05/08/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:TERNTerns Pharmaceuticals Inc
01/08/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:TERNTerns Pharmaceuticals Inc
29/07/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO TransitionNASDAQ:TERNTerns Pharmaceuticals Inc
21/06/202419:30GlobeNewswire Inc.Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference ParticipationNASDAQ:TERNTerns Pharmaceuticals Inc
14/06/202419:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TERNTerns Pharmaceuticals Inc
03/06/202417:10GlobeNewswire Inc.Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:TERNTerns Pharmaceuticals Inc
30/05/202409:05GlobeNewswire Inc.Terns Pharmaceuticals to Participate in Upcoming June Investor ConferencesNASDAQ:TERNTerns Pharmaceuticals Inc
17/05/202417:05GlobeNewswire Inc.Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics DayNASDAQ:TERNTerns Pharmaceuticals Inc
13/05/202409:05GlobeNewswire Inc.Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:TERNTerns Pharmaceuticals Inc
08/05/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Announces Leadership ChangesNASDAQ:TERNTerns Pharmaceuticals Inc
07/05/202417:05GlobeNewswire Inc.Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024NASDAQ:TERNTerns Pharmaceuticals Inc
29/04/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive DifferentiationNASDAQ:TERNTerns Pharmaceuticals Inc
10/04/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerNASDAQ:TERNTerns Pharmaceuticals Inc
14/03/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:TERNTerns Pharmaceuticals Inc
11/03/202417:05GlobeNewswire Inc.Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaNASDAQ:TERNTerns Pharmaceuticals Inc
27/02/202418:05GlobeNewswire Inc.Terns Pharmaceuticals to Participate in Upcoming March Investor ConferencesNASDAQ:TERNTerns Pharmaceuticals Inc
15/02/202420:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TERNTerns Pharmaceuticals Inc
14/02/202410:57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TERNTerns Pharmaceuticals Inc
07/02/202418:05GlobeNewswire Inc.Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:TERNTerns Pharmaceuticals Inc
07/02/202410:05GlobeNewswire Inc.Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive OfficerNASDAQ:TERNTerns Pharmaceuticals Inc
04/01/202418:05GlobeNewswire Inc.Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TERNTerns Pharmaceuticals Inc
29/11/202318:05GlobeNewswire Inc.Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:TERNTerns Pharmaceuticals Inc
27/11/202318:05GlobeNewswire Inc.Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive OfficerNASDAQ:TERNTerns Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TERN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados